Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled PC945 for Fungal Bronchitis in Asthma and Chronic Respiratory Disease
NCT03745196Phase 2Terminated
- Sponsor
- Pulmocide
- Start
- Nov 2018
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of opelconazole in pulmonary aspergillosis, Candida pneumonia, fungal bronchitis, sponsored by Pulmocide. Started Nov 2018; status: terminated.
02
Drugs
opelconazole
03
Conditions
pulmonary aspergillosisCandida pneumoniafungal bronchitis
Beyond the preview
Go deeper on NCT03745196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745196.